<DOC>
	<DOCNO>NCT00715039</DOCNO>
	<brief_summary>The study assess performance characteristic new measure ass onset efficacy GAD patient population .</brief_summary>
	<brief_title>Clinical Study Assessing New Scale Measure Onset Action Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Primary Diagnosis GAD ( DSM IV , 300.02 ) establish clinician use source data include MINI structure interview HAM A score ³20 Screening ( Study Day 7 ) Baseline ( Study Day 1 ) Visits observer rating Good health determine medical history , physical examination , vital sign , electrocardiography ( ECG ) , clinical laboratory measurement Covi Anxiety Scale total score ³9 Raskin Depression Scale total score £7 Screening Visit ( ensure predominance anxiety symptom depression symptom ) Age 18 65 ( inclusive ) Patients current DSMIV Axis I disorder . Patients current past schizophrenia , Psychotic disorder Delirium , dementia , amnestic , clinically significant cognitive disorder Bipolar schizoaffective disorder Benzodiazepine abuse dependence ; and/or Factitious disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>generalize anxiety disorder</keyword>
	<keyword>onset efficacy</keyword>
	<keyword>Daily Assessment Symptoms-Anxiety ( DAS-A )</keyword>
	<keyword>Methods</keyword>
</DOC>